+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antiviral Drugs Market - Global Forecast 2026-2032- Product Image
Antiviral Drugs Market - Global Forecast 2026-2032- Product Image
New

Antiviral Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 193 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904660
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The antiviral drugs market is evolving rapidly as breakthroughs in science, regulatory shifts, and new care delivery models disrupt established paradigms. Senior leaders face a complex landscape where operational resilience, innovation, and clinical value delivery are essential to maintaining competitiveness.

Market Snapshot: Antiviral Drugs Market Overview

The antiviral drugs market is sustaining strong growth momentum, beginning at USD 62.81 billion in 2025 and advancing to USD 65.92 billion in 2026, with projection to reach USD 100.83 billion by 2032 at a CAGR of 6.99%. This positive trajectory is propelled by the launch of novel therapeutics, ongoing investments in research, and regulatory realignments that support accelerated market access. Expanding pipelines and the adoption of advanced drug delivery technologies are responding to demands for faster time-to-market and improved patient access. These dynamics position the market for continued expansion across both established economies and high-growth emerging regions.

Scope & Segmentation Analysis

  • Indications: Includes Hepatitis B, Hepatitis C, Herpes Simplex, HIV, Influenza, and Respiratory Syncytial Virus therapies, addressing a spectrum of acute and chronic infections that drive ongoing innovation, clinical research, and treatment protocol updates.
  • Drug Classes: Covers fusion inhibitors, integrase inhibitors, non-nucleoside reverse transcriptase inhibitors, nucleoside analogues, and protease inhibitors. Each class serves unique roles in resistance management and aligns with patient safety requirements.
  • Routes of Administration: Comprises oral, injectable, inhaled, and topical forms, enabling customizable treatment pathways and posing distinct supply chain, storage, and adherence challenges for providers.
  • Distribution Channels: Spans clinics, hospital pharmacies, retail pharmacies, and online pharmacies. These channels reflect regional access models and support various reimbursement and distribution strategies.
  • End Users: Includes clinics, hospitals, home care, and long-term care facilities. Each setting presents different workflow demands and integration needs that affect uptake and continuity of care.
  • Geographies: Reviews the Americas, Europe, Middle East & Africa, and Asia-Pacific. Regional trends drive differentiated go-to-market approaches and influence regulatory and investment decisions across diverse healthcare systems.
  • Technology Platforms: Encompasses small molecules, biologics, long-acting injectables, nucleic acid therapies, and companion diagnostics. These innovation pipelines are central to evolving sector capabilities, introducing new modalities, and supporting targeted therapy strategies.

Key Takeaways for Decision-Makers

  • Therapeutic innovations are transforming clinical care approaches and broadening treatment options, influencing the development of updated protocols in antiviral management.
  • Adoption of emerging technologies such as modular chemistry and AI-driven platforms is notably reducing research and development timelines and enhancing candidate evaluation accuracy.
  • Regulatory bodies are placing increased emphasis on real-world evidence and post-market surveillance, which is shaping both regulatory approval processes and payer policy frameworks.
  • Diagnostics are being more closely integrated with therapeutics, supporting test-and-treat models that help address drug resistance and inform personalized care plans.
  • Resilient supply chain strategies, including regional manufacturing footprints and multi-source procurement, are becoming fundamental to mitigate risk and ensure product continuity in supply-sensitive markets.
  • Patient-focused innovations—such as digital adherence tools and advanced drug delivery systems—are driving improvements in care model efficiency and supporting wider access to antiviral therapies.

Tariff Impact on Supply Chains and Market Dynamics

Recent US tariff revisions are influencing antiviral drug supply chains, prompting organizations to reassess sourcing strategies and shift production closer to key markets. Cost shifts for active pharmaceutical ingredients and excipients are encouraging dual sourcing and regionalized manufacturing, while collaborative distribution frameworks are emerging to safeguard supply continuity. These adjustments are not only managing tariff-induced risk but also driving changes in manufacturing partnerships and distribution agreements, ultimately informing how organizations approach both procurement and market entry for new antiviral therapies.

Methodology & Data Sources

This analysis utilizes systematic reviews of peer-reviewed research, recent regulatory guidance, and structured interviews with clinicians, payers, manufacturers, and commercial leaders. Techniques applied include mapping of drug development pipelines, assessment of marketplace readiness, and scenario-based policy risk analysis, with findings validated through triangulation to support robust and actionable insights.

Why This Report Matters

  • Delivers practical intelligence to streamline antiviral program development and commercialization across the full product lifecycle, informing early-stage to post-launch planning.
  • Enables leadership to effectively manage regulatory and tariff-driven change through in-depth segmentation analysis, supply chain strategies, and clear visibility of market entry levers.
  • Facilitates confident decision-making by clarifying regional and technological trends that influence resource allocation and maximize operational effectiveness in a competitive environment.

Conclusion

This report equips senior stakeholders with timely, actionable insight to guide strategic planning, strengthen market positioning, and meet the evolving demands of the antiviral drugs sector.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Antiviral Drugs Market, by Indication
8.1. Hepatitis B
8.2. Hepatitis C
8.3. Herpes Simplex
8.4. Hiv
8.5. Influenza
8.6. Respiratory Syncytial Virus
9. Antiviral Drugs Market, by Drug Class
9.1. Fusion Inhibitors
9.2. Integrase Inhibitors
9.3. Non Nucleoside Reverse Transcriptase Inhibitors
9.4. Nucleoside Analogues
9.5. Protease Inhibitors
10. Antiviral Drugs Market, by Route Of Administration
10.1. Inhalation
10.2. Injectable
10.3. Oral
10.4. Topical
11. Antiviral Drugs Market, by End User
11.1. Clinics
11.2. Home Care
11.3. Hospitals
11.4. Long Term Care Facilities
12. Antiviral Drugs Market, by Distribution Channel
12.1. Clinics
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
13. Antiviral Drugs Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Antiviral Drugs Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Antiviral Drugs Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Antiviral Drugs Market
17. China Antiviral Drugs Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. AbbVie Inc.
18.6. AstraZeneca plc
18.7. Aurobindo Pharma Limited
18.8. Bayer AG
18.9. Boehringer Ingelheim GmbH
18.10. Bristol-Myers Squibb Company
18.11. Cipla Limited
18.12. Dr. Reddy’s Laboratories Ltd.
18.13. Gilead Sciences, Inc.
18.14. GlaxoSmithKline plc
18.15. Hetero Labs Limited
18.16. Johnson & Johnson
18.17. Merck & Co., Inc.
18.18. Mylan N.V.
18.19. Novartis AG
18.20. Pfizer Inc.
18.21. Roche Holding AG
18.22. Sandoz International GmbH
18.23. Sanofi S.A.
18.24. Sun Pharmaceutical Industries Ltd.
18.25. Takeda Pharmaceutical Company Limited
18.26. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ANTIVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ANTIVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS C, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS C, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HERPES SIMPLEX, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HERPES SIMPLEX, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HERPES SIMPLEX, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HIV, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HIV, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HIV, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INTEGRASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INTEGRASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 78. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 79. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 80. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 81. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 82. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 83. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 86. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 89. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 91. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 93. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 94. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 101. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 103. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 104. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 105. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 106. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 107. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 109. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 110. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 111. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 112. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 113. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 115. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 116. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 117. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 118. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 126. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 127. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 128. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 129. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 130. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 131. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 132. GCC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. GCC ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 134. GCC ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 135. GCC ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 136. GCC ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 137. GCC ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 138. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 140. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 141. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 142. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 143. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 144. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 145. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 146. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 147. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 148. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 149. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 150. G7 ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 151. G7 ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 152. G7 ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 153. G7 ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 154. G7 ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 155. G7 ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 156. NATO ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 157. NATO ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 158. NATO ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 159. NATO ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 160. NATO ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 161. NATO ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 162. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 163. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 164. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 165. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 166. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 167. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 168. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 169. CHINA ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 170. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 171. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 172. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 173. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 174. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Antiviral Drugs market report include:
  • AbbVie Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hetero Labs Limited
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sandoz International GmbH
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages193
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 65.92 Billion
Forecasted Market Value ( USD ) by 2032 $ 100.83 Billion
Compound Annual Growth Rate6.9%
Regions CoveredGlobal
No. of Companies Mentioned23

Related Topics

Related Reports

HIV Antivirals Market - Global Forecast 2025-2030 - Product Image

HIV Antivirals Market - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
Antiviral Therapeutics Market - Global Forecast 2026-2032 - Product Image

Antiviral Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Antiviral Combination Therapy Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Antiviral Combination Therapy Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Oral Antivirals Market - Global Strategic Business Report - Product Image

Oral Antivirals Market - Global Strategic Business Report

  • Report
  • 380 Pages
  • Global
From
Antiviral Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Antiviral Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 135 Pages
  • Global
From

About the Antivirals Market

The Antivirals market is a subset of the Infectious Diseases Drugs market, which includes drugs used to treat viral infections. Antivirals are used to treat a wide range of viral infections, including influenza, HIV, herpes, hepatitis, and other respiratory infections. Antivirals work by targeting the virus itself, preventing it from replicating and spreading throughout the body. They can also be used to reduce the severity of symptoms and shorten the duration of the illness. Antivirals are typically administered orally or intravenously, depending on the type of virus and the severity of the infection. In some cases, antivirals may be used in combination with other drugs to increase their effectiveness. Some of the major companies in the Antivirals market include Gilead Sciences, Merck & Co., Pfizer, GlaxoSmithKline, and Bristol-Myers Squibb. These companies produce a variety of antiviral drugs, including those used to treat influenza, HIV, herpes, and hepatitis. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.